CollPlant Biotechnologies Profit Margin

The latest profit margin for CLGN is -3934.91% as of June 2026. That compares with -541.34% in the prior-year period — down 626.9% year over year. That is below the Healthcare sector average of 21.34%. Investors often review this figure alongside CollPlant Biotechnologies's historical trend and sector peers before judging valuation or financial health.

Over the past year, CLGN's profit margin moved from -541.34% to -3934.91% — a 626.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in CollPlant Biotechnologies's valuation or profitability profile.

Against Healthcare companies, CLGN currently prints -3934.91% for profit margin, while the sector average sits near 21.34%. That is roughly 18543.3% below the sector mean. Large gaps often invite a closer look at CollPlant Biotechnologies's growth, margins, and balance sheet.

Profit Margin shows how effectively CollPlant Biotechnologies converts resources into returns. At -3934.91%, CLGN may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -541.34% in the prior-year period — down 626.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CLGN's profit margin (-3934.91%), review year-over-year change from -541.34%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.